Vertex Pharmaceuticals (Vertex) scored a 100 out of 100 on the 2023-2024 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Vertex increases the risk of dividing employees, alienating customers and harming shareholders. The company provides a benefits package for employees which covers transgender medical procedures for covered employees and dependents, including children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Vertex forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company provides formal ID&E learning for its senior leaders and released training on unconscious bias for all its employees. Vertex supports the Equality Act, a controversial bill. The company’s CEO, Reshma Kewalramani, signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. Vertex donated $1.5 million to the Boston Center for Antiracist Research, which is led by Ibram X. Kendi, who is noted for his work in support of critical race theory. For these reasons, Vertex receives a High Risk rating.